CAR-T Therapy for Complicated Lupus (Experimental Use)

By Dr. Robert Katz

If you follow lupus research, you may have heard about CAR-T cell therapy—an innovative treatment approach currently being investigated for people with complicated, refractory systemic lupus erythematosus (SLE). This experimental therapy is being studied primarily in patients who have not responded to conventional immunosuppressive treatments. Early clinical studies have shown promising results, including significant improvements in disease activity and, in some cases, sustained drug-free remission. This article explains what CAR-T therapy is and how it works.

White blood cells include several types, most notably T cells (thymus-derived) and B cells. In SLE, autoreactive B cells play a central role in driving disease by producing pathogenic autoantibodies that mistakenly attack the body’s own tissues.

CAR-T therapy is a highly personalized form of immunotherapy. In this approach, a patient’s own T cells are collected from the blood and genetically modified in a laboratory to express a synthetic receptor known as a chimeric antigen receptor (CAR). This receptor is specifically engineered to recognize a protein found on B cells—most commonly CD19.

The modified T cells, called CAR-T cells, are then expanded into millions of copies. Before these cells are reinfused, patients receive a short course of lymphodepleting chemotherapy. This step helps create space in the immune system so the CAR-T cells can function more effectively.

Once administered intravenously, CAR-T cells circulate throughout the body, selectively bind to B cells, and eliminate them. By targeting and removing autoreactive B cells, CAR-T therapy can markedly reduce lupus-related immune activity. In some reported cases, this has resulted in deep remission and a possible immune “reset,” allowing patients to remain symptom-free without ongoing immunosuppressive medications for extended periods.

Despite these encouraging findings, CAR-T therapy for lupus remains experimental. Its use is currently limited to individuals with severe, treatment-resistant disease and is available only through clinical trials or at specialized medical centers. Researchers continue to study its long-term safety, durability of response, and the risk of disease relapse.